Multiple drug use is very common in the elderly， which will significantly increase drug interactions and adverse drug reactions. Cardiovascular disease complicated with neuropsychiatric disease is the most common multi-disease comorbidity among the elderly， and it is also one of the disease combinations involving the most multiple drug use. In order to reduce the adverse clinical outcomes of the elderly in China， Chinese Society of Clinical Pharmacy of Chinese Medical Association organized relevant experts to develop Expert Consensus on Risk Prevention and Control of Multiple Drug Use in Elderly Patients with Cardiovascular Diseases and Neuropsychiatric Diseases in China by using foreign drug use risk assessment tools and combining relevant evidence-based results， and further promote its application in clinical disease treatment practice to reduce the adverse clinical outcomes of the elderly in China.

Background Atrial fibrillation (AF) is a common arrhythmia associated with increased cardiovascular morbidity and mortality. This study was undertaken to analyze the epidemiological factors and evaluate the current status of treatment in patients with AF in Mainland China. Methods Retrospective analysis of hospital records were taken from patients with primary diagnosis of AF, discharged from January 1999 to December 2001. A total of 9297 cases (mean age 65.5 years) with AF were enrolled from 40 hospitals in major parts of China. Results The percentage of hospital admissions with AF was gradually increased comparing to those of total cardiovascular admission during three years, with the average of 7.9%. The cases distribution progressively rose with age. The causes and associated conditions of AF: advanced age 58.1%, hypertension 40.3%, coronary heart disease 34.8%, heart failure 33.1%, rheumatic valvular disease 23.9%, idiopathic AF 7.4%, cardiomyopathy 5.4%, diabetes 4.1%. The most common coexistence among these variables was advanced age with hypertension. Permanent AF almost accounted for half of these cases (49.5%), paroxysmal and persistent AF were 33.7% and 16.7%, respectively. Paroxysmal AF was mainly treated with rhythm control (56.4%). However, 82.8% of patients with chronic AF had therapeutic strategy of rate control. In patients with persistent AF, the cardioversion had been attempted in cases more than 50%, with only 31.1% of these patients who could maintain stabilized sinus rhythm. The prevalence of stroke in this group was 17.5%. In nonvalvular AF patients the risk factors that significantly associated with stroke included advanced age, history of hypertension, coronary heart disease and type of AF. Sixty-four point five percent of these patients received antithrombotic therapy with dominated use of antiplatelet agents. The long-term prevention with anticoagulants only accounted for 6.6%. In this investigation patients with antiplatelets as well as patients with anticoagulants showed significant lower stroke rate in comparison with those managed neither. However, the difference between antiplatelets and anticoagulants in terms of stroke rate was not significant. Conclusions Most epidemiological factors of AF from this group showed highly in accordance with those from the reports from other countries, such as age distribution, causes and associated conditions, type of AF, dominantly with approach of rate control. Both antiplatelet and anticoagulant treatments significantly reduced stroke rate. But there was no significant difference between these two kinds of treatments in reducing stroke rate.

The incidence of retroperitoneal tumor is low, and treatment is difficult.According to the recent updates of evidence-based medical evidence at home and abroad, the consensus on the standardized treatment of retroperitoneal tumors were discussed including examination and diagnosis , surgical treatment comprehensive treatment, nutrition, rehabilitation, and review and follow-up, etc.
Antineoplastic Agents ; administration & dosage ; adverse effects ; therapeutic use ; China ; Consensus ; Delivery of Health Care ; standards ; Humans ; Practice Guidelines as Topic ; Retroperitoneal Neoplasms ; diagnosis ; drug therapy ; pathology

‍Liver cirrhosis （LC） is the terminal pathological stage of various chronic liver diseases and is characterized by chronic inflammation， diffuse fibrosis， pseudolobular formation， and portal-systemic collateral circulation， which belongs to the category of jaundice， hypochondriac pain， and abdominal distension in traditional Chinese medicine. At present， there is still a lack of specific clinical treatment methods， and integrated traditional Chinese and Western medicine therapy can effectively delay the progression of LC. Based on the principle of evidence-based medicine and with reference to the summary of recent clinical practice and the latest guidelines and expert consensus published in China and globally， the guidelines in this article are formed by objectively evaluating the evidence of integrated traditional Chinese and Western medicine diagnosis and treatment of LC and extensively soliciting the opinions of experts in the fields of traditional Chinese medicine， clinical medicine， and clinical epidemiology， so as to provide a reference for integrated traditional Chinese and Western medicine diagnosis and treatment of LC in clinical practice.

OBJECTIVE: To investigate the radiosensitizing effect of PP2A inhibition on nasopharyngeal carcinoma cells and its xenografts. METHODS: Co-immunoprecipitation and flow cytometry were used to examine PP2A activity, cell cycle analysis and apoptosis of CNE1 and its xenografts, in order to explore the effect of radiosensitization in CNE1 cells. RESULTS: Cell cycle distribution and apoptosis were measured by flow cytometry 24 h after treatment. The combination of 8 Gy and 40 μmol < L-1 norcantharidin produced significantly accumulation of cells in G2/M-phase( 45.71 ±2.015)% and more apoptosis(75.63 ± 6.11)% in CNE1 cell lines compared with norcantharidin alone and to radiation alone, norcantharidin in combination with radiation produced the greatest effects on tumor growth slowing and decreasing tumor weight by 87.64% relative to vehicle in CNE1 xenografts. Our data demonstrate that inhibition of PP2 A with radiation significantly sensitizes nasopharyngeal carcinoma cell lines in vitro and in vivo. CONCLUSION: The inhibition of PP2A with norcantharidin inhibited xenograft growth obviously. Our results support further exploration of PP2A inhibition as part of radiotherapy regimens for NPC and potentially other solid tumors.

Antineoplastic Agents ; adverse effects ; Consensus ; Gastrointestinal Neoplasms ; drug therapy ; Gastrointestinal Stromal Tumors ; drug therapy ; Humans ; Protein Kinase Inhibitors ; adverse effects

Effective lipid management can significantly reduce the burden of atherosclerotic cardiovascular disease(ASCVD).However,lipid management for ASCVD prevention and treatment in China still faces the challenges of low attainment rate and poor adherence.An increasing body of evidence suggests that a single-pill combination(SPC)of statin and non-statin agents is effective for improving blood lipid control rate,improving treatment adherence,and reducing adverse cardiovascular events.To standardize the clinical application of the cholesterol-lowering single-pill combination therapy in China,the"Chinese Expert Consensus on Clinical Application of Single-pill Combination of Cholesterol-lowering Agents"was developed with the efforts of a number of domestic experts from cardiovascular,cerebrovascular,endocrinological,and pharmacological fields.The advantages in clinical application and clinical research of cholesterol-lowering SPC were elaborated in this consensus,and the clinical pathway of lipid management for ASCVD prevention and treatment was formulated.Meanwhile,suggestions on the applicable population,usage and dosage,and management of adverse events of cholesterol-lowering SPC were provided.

Brain Injuries ; Child, Preschool ; Consensus ; Energy Intake ; Humans ; Infant ; Infant Nutritional Physiological Phenomena

Chromosome Aberrations ; Consensus ; Cytogenetics ; Humans ; Multiple Myeloma